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Johan van der Merwe and Filip Casselman ABSTRACT
INTRODUCTION
Atrial myxoma (AM) is the most common benign cardiac 
neoplasm, originating from multipotent mesenchymal cells and 
commonly presents in women between the third and sixth 
decades of life.(1) Large AM may result in ventricular inflow 
obstruction(2-3) and the safety of conventional sternotomy resec-
tion by single- or bi-atrial access, is well described.(4-6) We are 
currently witnessing an ongoing paradigm shift towards minimally 
invasive cardiac surgery (MICS), particularly in the first world, 
perhaps less so in Africa. The first South African MICS programme 
was initiated in 2011 and specialised centres that provide 
comprehensive minimally invasive- and catheter-based cardio-
vascular services are evolving. We have performed more than 
3 000 EPAS procedures at our institution since February 1997 
and have previously reported on our experience with intra-
cardiac oncological surgery.(7) In this report, we describe the 
successful resection of a massive obstructive AM in an 81-year-
old patient, which is to our knowledge, the largest documented 
AM ever resected by either robotic or endoscopic cardiac surgery.
CASE REPORT  
Clinical- and trans-thoracic echocardiographic (TTE) imaging 
review of an 81-year-old female identified a massive left atrial 
mass that originated from the intra-atrial septum and partially 
obstructed the mitral valve and left ventricular inflow (Figure 1). 
She presented with progressive New York Heart Association 
(NYHA) Class III symptoms and systolic pulmonary artery 
pressure (sPAP) of 65mm of mercury (mmHg). Additional 
investigations included coronary artery catheterisation, thoracic- 
and aorta-iliac axis computerised tomography and pulmonary 
function tests. Surgical excision was proposed by our multi-
disciplinary team and the patient elected the option of EPAS 
with a predicted EuroSCORE II of 3.4%. 
We routinely utilise double lumen endotracheal intubation and 
established a 3 - 4cm antero-lateral working port over the 
fourth intercostal space. Peripheral cardiopulmonary bypass 
(CPB) was established over trans-esophageal echocardiographic 
We are witnessing an ongoing worldwide paradigm shift 
from conventional sternotomy access towards minimally 
invasive cardiac surgery (MICS). Endoscopic port access 
surgery (EPAS) is well established for the safe and 
durable resection of atrial myxoma (AM) and considered, 
by experienced surgeons to be a good MICS training 
platform once the initial EPAS learning curves are 
mastered. We report on the successful EPAS resec-
tion of an 8.5cm obstructive left AM in an 81-year-old 
patient, which is to our knowledge, the largest AM ever 
resected by robotic, or endoscopic, cardiac surgery. 
Post-operative recovery was uneventful and the patient 
was discharged home on the fi fth post-operative day. 
Clinical and echocardiographic follow-up at 12 months 
confi rmed an excellent functional recovery and the 
absence of residual or recurrent, tumour. This case aims 
to provide insights into the advantages and limitations 
of this approach.  SAHeart 2016;13:302-303
FIGURE 1: Trans-esophageal echocardiographic (TEE) images 















(TEE) guided guidewires through the right internal jugular vein 
(16F, Optisite™, Edwards Lifesciences, Irvine, California, USA), 
right femoral vein (25F, Quickdraw™, Edwards Lifesciences, 
Irvine, California, USA) and right femoral artery (23F, 
Endoreturn™, Edwards Lifesciences, Irvine, California, USA). 
An endo-aortic balloon (IntraClude™, Edwards Lifesciences, 
Irvine, California, USA) was used for aortic occlusion and cold 
antegrade crystalloid cardioplegia delivery. Cardioplegic arrest 
was uneventfully achieved and subsequent left atriotomy 
revealed the massive obstructive septal neoplasm. The risk of 
fragmentation prohibited the use of our usual endoscopic left 
atrial retractor (Figure 2A) and visualisation was ascertained 
with traction sutures. A broad septal resection around the 
tumour base was performed with long shafted instruments 
without tumour manipulation or intra-atrial septum perforation 
(Figure 2B). The endocardial defect was sutured and subsequent 
systematic mitral valve analysis uneventful. Further endoscopic 
inspection of the ventricular cavity confirmed no distal frag-
mentation. De-airing was ensured by flooding the operative 
field with CO2 and antegrade endo-aortic balloon venting 
under TEE guidance. CPB and ischaemic times were 115 and 76 
minutes respectively. Discontinuation of mechanical respiratory 
support was achieved within 6 hours post-operatively and 
discharge from intensive care occurred after 12 hours. In-
hospital TTE confirmed normal atrioventricular valve, chamber 
and ventricular function with no septal defect. Rapid clinical 
recovery warranted home discharge on the fifth post-operative 
day. NYHA class I clinical status was achieved after 6 weeks 
and remained unchanged at 12 month follow-up. Histological 
examination of the intact tumour confirmed the typical findings 
of an AM and resection margins free of neoplastic tissue 
(Figure 2C). Echocardiographic review at 12 month follow-up 
confirmed the absence of residual or recurrent atrial septal 
tumour and sPAP of 30mmHg. 
DISCUSSION 
The oncological principles and resection techniques of AM by 
conventional single or bi-atrial sternotomy approaches are well 
described.(4-6) We initiated our EPAS programme in 1997 and 
reported on the safety and durability of our approach in cardiac 
oncological surgery.(7) The targeted endoscopic left atrium and 
tumour visualisation minimise any unintentional cardiac 
manipulation, tumour fragmentation and risk of embolisation. 
Left atriotomy suture retraction substituted routine atrial 
retractor placement and provided excellent exposure for intact 
tumour resection and atrial septal reconstruction. Patient 
recovery was swift and resulted in complete resolution of pre-
operative symptomatology. 
CONCLUSION  
Massive AM should not deter referring physicians and surgeons 
from offering patients the full range of benefits associated 
with MICS in experienced centres. Small, pedunculated and 
uncomplicated atrial myxoma can serve as an EPAS training 
platform once the initial technical principles of endoscopic 
surgery are mastered. 
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FIGURE 2: Targeted endoscopic visualisation of the massive atrial myxoma (A). Broad excision of the tumour base with long shafted instru-
ments (B). Pathological examination of an intact 8.5 x 4.2 x 2.5cm massive atrial myxoma (C).
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